Clinical trial
SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia…
NCT00301769 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00301769 |
|---|---|
| Title | SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia |
| Official title | A Phase I Study of SJG-136 in Patients With Advanced Leukemia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13, q22), Adult Acute Myeloid Leukemia With t(15, 17)(q22, q12), Adult Acute Myeloid Leukemia With t(16, 16)(p13, Adult Acute Myeloid Leukemia With t(8, 21)(q22 and 9 more |
| Intervention type | Drug |
| Interventions | SJG-136 |
| Enrollment | 25 |
| Start date | Dec 1, 2005 |
| Primary completion | Feb 1, 2009 |
| First posted | Mar 13, 2006 |
| Last update posted | Sep 30, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: